July 22, 2022 10:23 AM EDT R&D
J&J's BCMA/CD3 bispecific nabs a conditional EMA nod, jumping in front of FDATeclistamab is a bispecific antibody, engaging two targets at once.
https://endpts.com/jjs-bcma-cd3-bispecific-nabs-a-conditional-ema-nod-jumping-in-front-of-fda/
While one arm binds directly to specific antigens on cancer cells, the other directs the patient’s own T-cells to kill them. In this case, teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells.https://endpts.com/jjs-bcma-cd3-bispecific-nabs-a-conditional-ema-nod-jumping-in-front-of-fda/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |